At VeonGen Therapeutics, our drive comes from advancing science into tangible therapies. Building on years of expertise as VeonGen, we are now a clinical-stage company dedicated to addressing inherited retinal diseases with innovative AAV-based gene therapy platforms. What motivates us is the precision of science and the opportunity to pioneer new delivery approaches that expand the potential of gene therapy. Our lead programs, VG801 for Stargardt disease and ABCA4-related retinopathies, and VG901 for CNGA1-related retinitis pigmentosa, represent first-in-class innovations designed to meet high unmet needs. With FDA Rare Pediatric Disease Designations and early clinical trials underway, we remain focused on translating groundbreaking research into rigorous clinical solutions. Our vision is to redefine what is possible in ocular gene therapy and set new standards in the field.